What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after ...

Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 3.33% to $421.03 Wednesday, on what proved to be an all-around favorable ...

Inflation should have a minimal impact on these companies' financial results. And they also boast excellent growth prospects.

Vertex Pharmaceuticals (VRTX) has drawn attention with new data from its RUBY-3 trial, showing that povetacicept has achieved meaningful results in two kidney diseases. The recent FDA designations ...

Pennsylvania-based Conestoga Capital Advisors sold 855,435 Vertex shares for an estimated $24.8 million based on average prices for the quarter ended September 30. The change represents 0.4% of 13F ...

DexCom delivered 22% revenue growth in the third quarter. U.S. revenue grew 21% year over year, while revenue in Dexcom's ...

The tax software specialist delivered double-digit growth on the top line in its latest quarter. Adjusted net income also rose, albeit not as steeply. That morning, Vertex revealed that its total ...

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...